Showing 1091-1100 of 1395 results for "".
- Alcon Announces US Launch of Tryptyr for Dry Eye Diseasehttps://modernod.com/news/alcon-announces-us-launch-of-tryptyr-for-dry-eye-disease/2482908/Alcon announced the US commercial availability of Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of the signs and symptoms of dry eye disease (DED). Approved by the FDA in May, eye care professionals (ECPs) across the US can officially begin p
- FDA Accepts Aldeyra's NDA for Reproxalap in Dry Eye Disease; Expands Partnership with AbbViehttps://modernod.com/news/fda-accepts-aldeyras-nda-for-reproxalap-in-dry-eye-disease/2482547/Aldeyra Therapeutics announced that the FDA has officially accepted for review the resubmitted new drug application (NDA) for its topical ocular therapy, reproxalap, aimed at treating the signs and symptoms of dry eye disease. The FDA has set a Prescription Drug User Fee Act (PDUFA) target d
- After Shortage, Harrow Announces Relaunch of Triesencehttps://modernod.com/news/after-shortage-harrow-announces-relaunch-of-triesence/2482468/Harrow has officially relaunched Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid. Triesence is approved by the FDA for use in visualizing tissues during vitrectomy and treating ocular inflammatory conditions that do n
- Former Regenxbio Execs Announce Launch of Gene Therapy Company Tern Therapeuticshttps://modernod.com/news/former-regenxbio-execs-announce-launch-of-gene-therapy-company-turn-therapeutics/2482414/Tern Therapeutics announced its official launch alongside the successful closing of a $15 million financing round. Simultaneously, Tern revealed a global licensing agreement with Regenxbio to acquire two gene therapy programs—RGX-381 and RGX-181—now designated as TTX-381 and
- Clearside and Arctic Vision Report Data From Trial of Arcatis to Treat Uveitic Macular Edema in Chinahttps://modernod.com/news/clearside-and-arctic-vision-report-data-from-trial-of-arcatis-to-treat-uveitic-macular-edema-in-china/2482380/Clearside Biomedical announced that its partner, Arctic Vision, reported topline results from its phase 3 clinical trial of Arcatus (ARVN001) for the treatment of uveitic macular edema in China. In addition, Arctic Vision announced that new drug applications for Arcatus have been officially accep
- Nova Eye to Feature Several Presentations and Posters Related to iTrack Canaloplasty at 2024 ESCRS Annual Congresshttps://modernod.com/news/nova-eye-to-feature-several-presentations-and-posters-related-to-itrack-canaloplasty-at-2024-escrs-annual-congress/2482374/Nova Eye Medical has announced that the company’s proprietary canaloplasty technology platform (iTrack and iTrack Advance) will be featured in numerous presentations and posters during the official scientific program of the European Society of Cataract and Refractive Surgeons
- Optometry Giving Sight Earns Four-Star Rating From Charity Navigatorhttps://modernod.com/news/optometry-giving-sight-earns-four-star-rating-from-charity-navigator/2482001/Optometry Giving Sight (OGS) has announced that its strong financial health and ongoing accountability and transparency have earned a Four-Star rating from Charity Navigator. This rating designates Optometry Giving Sight as an official “Give with Confidence” charity, indicating t
- BVI launches Finevision HP Trifocal IOL in Japanhttps://modernod.com/news/bvi-launches-finevision-hp-trifocal-iol-in-japan/2481681/BVI has announced the launch of the Finevision HP hydrophobic and glistening free trifocal IOL in Japan. BVI Japan will host the official launch event at the upcoming Japanese Society of Cataract and Refractive Surgeons (JSCRS) annual meeting in Sapporo, Japan, June 22-24. Dr. Kazu
- CDC: Cases of Vision Loss and Death Due to Drug-Resistant Bacteria Linked to Artificial Tears Continues to Risehttps://modernod.com/news/cdc-cases-of-vision-loss-and-death-due-to-drug-resistant-bacteria-linked-to-artificial-tears-continues-to-rise/2481488/Federal officials say three people have died as part of a growing number of cases of infections from a rare, extensively drug-resistant strain of Pseudomonas aeruginosa found in some artificial tears. There have also been 8 reports of vision loss and 4 reports of enucleatio
- Alcon Presents Comprehensive Scientific Program With 59 Abstracts at ESCRS 2022https://modernod.com/news/alcon-presents-comprehensive-scientific-program-with-59-abstracts-at-escrs-2022/2481096/Alcon will present extensive data during the 2022 Congress of the European Society of Cataract and Refractive Surgery (ESCRS), a hybrid event taking place both virtually and in Milan, Italy, September 16-20. The official program will feature 59 abstracts, with more than 30 focused on Alcon’